NTRK fusion-positive NSCLC: perspectives from pathology, oncology and beyond
Tuesday 11 November, 2025
at 16:00 GMT / 17:00 CET / 11:00 EST
75 minutes
Join Justin Gainor, Luis Paz-Ares, Lynette Sholl and Stevan Bradford for a discussion- and case-based-webinar exploring the latest in NTRK fusion-positive non-small cell lung cancer (NSCLC).
Learn how to:
- Detect rare NTRK fusions using current best practices
- Optimize treatment with TRK inhibitors
- Navigate access barriers and engage patients in shared decision-making
This webinar is aimed at oncologists, pathologists, pulmonologists, nurses and nurse practitioners, and all other members of the MDT team managing NSCLC patients.
Learning objectives
After taking part in this program, learners will be able to:
- Integrate appropriate methods for detecting molecular biomarkers in NSCLC, including rare alterations like NTRK fusions
- Evaluate efficacy and safety data supporting TRK inhibitors for NTRK fusion-positive NSCLC
- Implement shared decision-making strategies that reflect patient values and concerns
- Recognize barriers to accessing TRK inhibitors and explore strategies to improve treatment access
Agenda
- Welcome and introduction 5 mins
- Detecting NTRK fusions: pathology case focus 10 mins
- Management of NTRK fusion-positive NSCLC: oncology case focus 10 mins
- NTRK-targeted therapies: a safety perspective 10 mins
- Navigating NTRK: a patient’s perspective 15 mins
- Panel discussion / live audience Q&A 15 mins
- Summary and close 5 mins
Meet the faculty
Program Director
Justin Gainor, MD
Assistant Professor of Medicine, Harvard Medical School
Director, Center for Thoracic Cancers, Massachusetts General Hospital
Director, Targeted Immunotherapy, Henri and Belinda Termeer Center for Targeted Therapies
Dr. Justin Gainor is a thoracic medical oncologist and Director of the Center for Thoracic Cancers at Massachusetts General Hospital (MGH). He also serves as Director of Targeted Immunotherapy at the Henri and Belinda Termeer Center for Targeted Therapies at MGH and is Co-leader of the Dana-Farber/Harvard Cancer Center Lung Program. Dr. Gainor holds the academic title of Assistant Professor of Medicine at Harvard Medical School. His clinical and research interests focus on thoracic malignancies and immunotherapy.
Disclosures
Grants/Research Support: Takeda
Honoraria/Consulting Fees: AI Proteins, Amgen, Arcus, AstraZeneca, BeiGene, Blueprint Medicines, Bristol-Myers Squibb, Ellipses Pharma, Genentech/Roche, Ironwood Pharmaceuticals, iTeos, Jazz Pharmaceuticals, Karyopharm, Loxo/Lilly, Mariana Oncology (Curie), Merck, Merus Pharmaceuticals, Mirati, Novartis, Nuvalent, Pfizer, Sanofi, Silverback Therapeutics, Takeda, Tempus
Equity/Stock Ownership: AI Proteins
Spouse/Partner Employment: Ironwood Pharmaceuticals
Other Support: AI Proteins (Advisory Board, Consulting, Equity)
Luis Paz-Ares, MD, PhD
Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Head, Lung Cancer Unit, Spanish National Cancer Research Center (CNIO)
Dr. Luis Paz-Ares is Chair of the Medical Oncology Department at Hospital Universitario 12 de Octubre and Head of the Lung Cancer Unit at CNIO in Madrid. He also serves as Associate Professor at Universidad Complutense de Madrid and is a member of the Real Academia de Farmacia de Galicia.
He trained in medical oncology in Madrid and Glasgow, and has held leadership roles in oncology departments across Spain. His research focuses on lung cancer and the development of novel therapies, with over 340 publications in leading journals including NEJM, Lancet, and JCO. Dr. Paz-Ares has served on scientific committees for ASCO, ESMO, EORTC, and regulatory agencies including the Spanish Agency of Medicines and the European Medicines Agency. Dr. Paz-Ares is Chief Medical Officer of the Spanish Association Against Cancer (AECC), where he also serves on the Board.
Disclosures
Grants/Research Support (paid to institution): AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme (MSD), Pfizer, Roche
Honoraria/Consulting Fees: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, BeOne, BeiGene, BMS, Boehringer Ingelheim, Daiichi Sankyo, Gilead, GSK, Janssen, Lilly, Medscape, Merck, Mirati, MSD, Novartis, Pharmamar, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda
Speaker’s Bureau Participation: AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Merck, MSD, Novartis, Pfizer, Pharmamar, Janssen, Regeneron, Roche
Equity/Stock Ownership: Altum Sequencing, Stab Therapeutics
Spouse/Partner Employment: Amgen, Astellas, Crinetics Pharmaceuticals, Esteve, HUTCHMED, Ipsen, ITM, Merck, Novartis, Pfizer, Roche, Sanofi, Servier
Lynette M. Sholl, MD
Pathologist, Brigham and Women’s Hospital
Professor of Pathology, Harvard Medical School
Dr. Lynette M. Sholl is a pathologist at Brigham and Women’s Hospital in Boston and Professor of Pathology at Harvard Medical School. She completed her medical school training at Stanford University School of Medicine, an internship in internal medicine at the Hospital of University of Pennsylvania, anatomic pathology residency and fellowship at Brigham and Women’s Hospital, and the molecular genetics pathology fellowship at the Harvard teaching hospitals. Her research interests include predictive tumor characterization and clinical validation of novel molecular and immunohistochemical tests for lung cancers. Dr. Sholl’s responsibilities include serving as the Division Chief for Molecular Diagnostics at Mass General Brigham and as Chief of the Pulmonary Pathology Service at Brigham and Women’s Hospital.
Disclosures
Grants/Research Support: Bristol Myers Squibb, Genentech
Honoraria/Consulting Fees: Genentech, Lilly
Stevan Bradford
Patient, USA
Stevan has worked in the industrial field for many years and is currently a shift coordinator at a steel mill, overseeing acid regeneration operations. He’s passionate about the outdoors and enjoys spending time in state parks, hiking, boating, fishing, and photography. His favourite quote is Emerson’s “In the woods we return to reason and faith”, which reflects his deep connection to nature and resilience through life’s challenges.
Disclosures
Nothing to disclose.
Accreditation
An application has been made to the UEMS EACCME® for CME accreditation of this event.
This program is aligned with Springer Medicine – an English-language, medical education platform provided by the Springer Nature Group. Springer Medicine supports doctors in their ongoing quest for optimal patient care, and delivers the latest evidence on new therapies, practice guidelines and news in easily digestible formats to keep healthcare professionals effortlessly up to date.
